Multimodal Therapeutic Approach for a Severe Case of Kaposiform Lymphangiomatosis: From Procedural Interventions to Targeted Therapies
May 2024
in “
Pediatric Blood & Cancer
”
Studysummary In this case study, a transition to the MEK inhibitor trametinib successfully stabilized disease and reduced toxicity in a patient with refractory kaposiform lymphangiomatosis after prolonged sirolimus and steroid treatment.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This case study describes a severe instance of kaposiform lymphangiomatosis (KLA) in a 10-year-old girl, highlighting the challenges and successes of a multimodal therapeutic approach. Initially treated with sirolimus, prednisone, and vincristine, the patient's condition worsened, necessitating a tracheostomy and frequent transfusions. A combination of endovascular embolizations and sclerotherapy stabilized her condition, but she remained steroid-dependent. Genetic testing revealed an NRAS mutation, leading to the introduction of the MEK inhibitor trametinib, which improved her condition significantly after 20 months of monotherapy. The study emphasizes the potential of trametinib as an alternative treatment for severe KLA, especially when traditional therapies like sirolimus and steroids are ineffective or cause long-term toxicities.
